Literature DB >> 25640156

Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.

E Sturegård1, K A Ängeby2, J Werngren3, P Juréen3, G Kronvall4, C G Giske4, G Kahlmeter5, T Schön6.   

Abstract

The MIC wild-type (WT) distribution for Mycobacterium tuberculosis in BACTEC 960 MGIT is not defined, which may result in poor reproducibility for drug susceptibility testing (DST), as several DST methods with different breakpoints are in use. In a comparison between MGIT and Middlebrook 7H10 medium of seven first- and second-line drugs, including 133 MIC determinations of 15 WT isolates, we found an agreement of 91.7% within ± one MIC dilution step. The results confirm the agreement in MIC testing between 7H10 and MGIT and indicate that breakpoints could be harmonized in order to avoid misclassification.
Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug susceptibility testing; epidemiological cut off; minimal inhibitory concentration; normalised resistance interpretation; resistance; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 25640156     DOI: 10.1016/j.cmi.2014.08.021

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  5 in total

1.  1,4-Benzoquinone antimicrobial agents against Staphylococcus aureus and Mycobacterium tuberculosis derived from scorpion venom.

Authors:  Edson Norberto Carcamo-Noriega; Shyam Sathyamoorthi; Shibdas Banerjee; Elumalai Gnanamani; Monserrat Mendoza-Trujillo; Dulce Mata-Espinosa; Rogelio Hernández-Pando; José Ignacio Veytia-Bucheli; Lourival D Possani; Richard N Zare
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-10       Impact factor: 11.205

2.  Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.

Authors:  Robin J Svensson; Katarina Niward; Lina Davies Forsman; Judith Bruchfeld; Jakob Paues; Erik Eliasson; Thomas Schön; Ulrika S H Simonsson
Journal:  Br J Clin Pharmacol       Date:  2019-07-25       Impact factor: 4.335

3.  A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis.

Authors:  Erik Tenland; Nitya Krishnan; Anna Rönnholm; Sadaf Kalsum; Manoj Puthia; Matthias Mörgelin; Mina Davoudi; Magdalena Otrocka; Nader Alaridah; Izabela Glegola-Madejska; Erik Sturegård; Artur Schmidtchen; Maria Lerm; Brian D Robertson; Gabriela Godaly
Journal:  Tuberculosis (Edinb)       Date:  2018-10-30       Impact factor: 3.131

4.  Development of a Mucoadhesive Liquid Crystal System for the Administration of Rifampicin Applicable in Tuberculosis Therapy.

Authors:  Kaio Pini Santos; Camila Fernanda Rodero; Camila Maríngolo Ribeiro; Maria P D Gremião; Rosângela Gonçalves Peccinini; Fernando Rogerio Pavan; Camron Pearce; Mercedes Gonzalez-Juarrero; Marlus Chorilli
Journal:  Life (Basel)       Date:  2022-07-28

5.  Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).

Authors:  David Ekqvist; Anna Bornefall; Daniel Augustinsson; Martina Sönnerbrandt; Michaela Jonsson Nordvall; Mats Fredrikson; Björn Carlsson; Mårten Sandstedt; Ulrika S H Simonsson; Jan-Willem C Alffenaar; Jakob Paues; Katarina Niward
Journal:  BMJ Open       Date:  2022-03-10       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.